



JIM GIBBONS
Governor

STATE OF NEVADA
DEPARTMENT OF HUMAN RESOURCES
DIVISION OF HEALTH CARE FINANCING AND POLICY
NEVADA MEDICAID

MICHAEL J. WILLDEN
Director

CHARLES DUARTE
Administrator

NOTICE OF OPEN PUBLIC MEETING

The Division of Health Care Financing and Policy (DHCFP) Pharmacy and Therapeutics Committee will conduct a public meeting on **June 25, 2009** beginning at **1:00 p.m.** at the following location:

**Las Vegas Chamber of Commerce
6671 Las Vegas Blvd. S., Suite 300
Las Vegas, NV**

Reasonable efforts will be made to assist and accommodate physically challenged persons desiring to attend the meeting. Please call Rita Mackie at: 775-684-3681 or email rmackie@dhecp.nv.gov in advance, but no later than two working days prior to the meeting, so that arrangements may be conveniently made.

Below is an agenda of all items scheduled to be considered. Unless otherwise noted, items may be taken out of order at the discretion of the Chairperson.

Public comment is limited to 3 minutes per individual, organization, or agency, but may be extended at the discretion of the Chairperson.

**draft
AGENDA**

- I. Call to Order and Roll Call
- II. *Review and Approval of March 26, 2009, Meeting Minutes

ANNUAL REVIEW- DRUG CLASSES WITH PROPOSED CHANGES

- III. Antidepressants: Other
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion on the PDL
- IV. Antiemetics: Oral, 5-HT3s
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion on the PDL

- V. Cardiovascular: Antihyperlipidemics: Triglyceride Lowering Agents
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. *Committee Discussion and Approval of Drugs for Inclusion on the PDL
- VI. Electrolyte Depleters
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. *Committee Discussion and Approval of Drugs for Inclusion on the PDL
- VII. Gastrointestinal Agents: PPIs
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. *Committee Discussion and Approval of Drugs for Inclusion on the PDL
- VIII. Intranasal Rhinitis Agents
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. *Committee Discussion and Approval of Drugs for Inclusion on the PDL
- IX. Respiratory: Inhaled Corticosteroids/Nebs
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. *Committee Discussion and Approval of Drugs for Inclusion on the PDL
- X. Urinary Tract Antispasmodics
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. *Committee Discussion and Approval of Drugs for Inclusion on the PDL

XI. Annual Review - Drug Classes without Proposed Changes

- A. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy without Changes
 - 1. Alzheimer's Agents
 - 2. Analgesics: Long Acting Narcotics
 - 3. Antibiotics: Cephalosporins 2nd Generation
 - 4. Antibiotics: Cephalosporins 3rd Generation
 - 5. Antibiotics: Macrolides
 - 6. Antibiotics: Quinolones 2nd Generation
 - 7. Antibiotics: Quinolones 3rd Generation
 - 8. Anticoagulants: Injectable
 - 9. Antidepressants: SSRIs
 - 10. Antifungals: Onychomycosis Agents
 - 11. Antihistamines: 2nd Generation
 - 12. Anti-Migraine Agents: Triptans
 - 13. Antiparkinson's Agents: Non-ergot Dopamine Agonists
 - 14. Benzoyl Peroxide and Clindamycin Combinations: Topical Agents
 - 15. Bone Ossification Agents: Bisphosphonates
 - 16. Cardiovascular: ACE Inhibitors & Diuretic Combinations
 - 17. Cardiovascular: Angiotensin II Receptor Blockers & Diuretic Combinations
 - 18. Cardiovascular: Antihyperlipidemics: Cholesterol Absorption Inhibitors
 - 19. Cardiovascular: Antihyperlipidemics: Niacin Agents
 - 20. Cardiovascular: Antihyperlipidemics: Statins & Statin Combinations
 - 21. Cardiovascular: Beta Blockers
 - 22. Cardiovascular: Calcium Channel Blockers & Combinations
 - 23. Central Nervous System: ADHD/Stimulants
 - 24. Central Nervous System: Sedative Hypnotics
 - 25. Direct Renin Inhibitors
 - 26. Erythropoiesis Stimulating Proteins
 - 27. Gastrointestinal Agents: H2RAs
 - 28. Growth Hormone Agents
 - 29. Hepatitis C Agents
 - 30. Herpetic Antiviral Agents
 - 31. Immunomodulators: Injectable
 - 32. Immunomodulators: Topical
 - 33. Impetigo Agents: Topical
 - 34. Leukotriene Modifiers
 - 35. Multiple Sclerosis Agents
 - 36. Nasal Calcitonins
 - 37. Ophthalmic Antihistamines
 - 38. Ophthalmic Glaucoma Agents
 - 39. Ophthalmic Non-Steroidal Anti-Inflammatory Agents
 - 40. Ophthalmic Quinolones
 - 41. Otic Fluoroquinolones
 - 42. Platelet Aggregation Inhibitors
 - 43. Pulmonary Arterial Hypertension Agents - Endothelin Receptor Antagonists
 - 44. Respiratory: Inhaled Anticholinergic Agents
 - 45. Respiratory: Long Acting Beta Adrenergics
 - 46. Respiratory: Short Acting Beta Adrenergic-Inhalers/Nebs
 - 47. Skeletal Muscle Relaxants
 - B. * Committee Discussion and Approval of Drug Classes without changes for the PDL
- XII. Report by FHSC on Brand Name Preferred Drugs Converted to Generic Status and the Extension of Existing Product Lines
- XIII. Report by FHSC on Botulinum Toxin Utilization
- XIV. Review of Next Meeting Location, Date, and Time

XV. Public Comment

XVI. *Adjournment

*** Denotes items, including subparts, on which an action may be taken.**

This notice and agenda has been posted on or before 9:00 a.m. on the third working day before the meeting at the following locations:

Notice of this meeting will be available on or after the posting date of this Agenda at the DHCFP Web site (dhcfp.state.nv.us).

Posting of the Agenda will be at the Nevada Medicaid Central offices in Carson City and Las Vegas; Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Humboldt County Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.

If requested in writing, a copy of the action items will be mailed to you or they may be reviewed Monday through Friday from 9:00 a.m. until 5:00 p.m., or at the meeting. Please call at least one day ahead for an appointment for document review. Written comments on the proposed changes may be sent to the DHCFP, 1100 E. William Street, Suite 102, Carson City, NV 89701.

All persons that have requested in writing to receive the Open Meeting Agenda have been duly notified by mail or e-mail.

Anyone presenting documents for consideration during the public comment portion of the meeting must provide sufficient copies for each member of the committee and the official record. Copies are to be distributed at the time of the meeting and should be provided at both meeting locations; DHCFP or its contractor will not distribute public comment information or materials prior to the public meeting.